Skip to main content
. Author manuscript; available in PMC: 2022 May 11.
Published in final edited form as: ACS Nano. 2021 Nov 8;15(11):16974–16981. doi: 10.1021/acsnano.1c09139

Figure 1. Probes and protocols for tumor-targeted radionuclide therapy.

Figure 1

A: Design of liposome-based radiotracers enabling MPS clearance of radioactivity via enzymatic cleavage of ester groups. Ether groups served as non-cleavable controls. B-D: PET scans of non-cleavable (B), esterase-labile (C), and folate-targeted esterase-labile liposomes (D) labeled with 124I and 131I in subcutaneous and orthotopic pancreatic tumors in mice. Images reproduced with permission from ref 14.